Table I.
Study | Type | Primary findings | (Refs.) |
---|---|---|---|
Song et al, 2019 | Research | NMN promotes osteogenesis via SIRT1 | (16) |
Zainabadi, 2019 | Review | NMN improve osteogenesis | (45) |
Liang et al, 2019 | Research | NMN alleviates aluminum-induced bone loss by inhibiting the thioredoxin-interacting protein-NLRP3 inflammasome | (42) |
Hassan et al, 2018 | Research | Nicotinamide phosphoribosyltransferase expression in osteoblasts controls osteoclast recruitment in alveolar bone remodeling | (46) |
Mills et al, 2016 | Research | Long-term NMN administration significantly improves bone density | (47) |
Baek et al, 2017 | Research | Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro | (48) |
Abed et al, 2014 | Research | Low SIRT1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity | (49) |
NMN, nicotinamide mononucleotide; SIRT1, sirtuin 1; NLRP3, nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3.